Acquisitions assistance Cornerstone

Cary drugmaker Cornerstone Therapeutics reported that fourth-quarter income jumped 48 percent after last years acquisitions of dual new products.

Revenue totaled $30.8 million for the entertain that finished Dec. 31. Profit for the entertain clocked in at $2.7 million, down somewhat from $2.9 million a year earlier.

The association outlayed some-more to marketplace the drugs.

For the full year, Cornerstone pennyless the $100 million income barrier. Revenue totaled $109.6 million, up from $64.9 million in 2008.

Last year was a main year for the business, CEO Craig Collard pronounced in an interview. "The products we have in place right away give us longer-term opportunities for growth," he said.

Cornerstone acquired the U.S. rights to Curosurf, used to provide a lung ailment that affects beforehand infants, and the antibiotic Factive in September.

With income from a little of the comparison products declining, the association has been in merger mode.

"We are assured we have the right plan to set up on the success," Collard said.

Cornerstone shares, that peaked on top of $11 in June, rose 47 cents Thursday to close at $5.73.